Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Non-Current Assets (2016 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Non-Current Assets for 10 consecutive years, with $581.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Non-Current Assets fell 15.31% to $581.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.3 billion, a 16.57% decrease, with the full-year FY2025 number at $581.0 million, down 15.31% from a year prior.
  • Non-Current Assets was $581.0 million for Q4 2025 at Ultragenyx Pharmaceutical, up from $547.2 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $758.8 million in Q4 2023 to a low of $526.8 million in Q1 2021.
  • A 5-year average of $636.0 million and a median of $638.4 million in 2021 define the central range for Non-Current Assets.
  • Peak YoY movement for Non-Current Assets: skyrocketed 60.93% in 2021, then dropped 25.92% in 2025.
  • Ultragenyx Pharmaceutical's Non-Current Assets stood at $665.8 million in 2021, then dropped by 0.64% to $661.5 million in 2022, then rose by 14.71% to $758.8 million in 2023, then decreased by 9.6% to $686.0 million in 2024, then fell by 15.31% to $581.0 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's Non-Current Assets are $581.0 million (Q4 2025), $547.2 million (Q3 2025), and $586.5 million (Q2 2025).